An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints
From MaRDI portal
Publication:3299101
Recommendations
- Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
- Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
- Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints
- A Bayesian Approach to the Design of Phase II Clinical Trials
- On optimal subset designs for phase II clinical trials with both total response and disease control
Cited in
(8)- Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
- Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
- Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome
- Bayesian Optimal Design for Phase II Screening Trials
- Bayesian design of biosimilars clinical programs involving multiple therapeutic indications
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints
- Stopping rules for phase II clinical trials: an overview
This page was built for publication: An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3299101)
